GLP-1 weight-loss drugs are popular but pricey. New data highlights use by age and gender - and why interest outpaces access for many.

Lilly shares fell after the company’s oral drug showed less weight loss than hoped. It could still be huge.

In an 18-month clinical trial of the experimental GLP-1 pill orforglipron, about 60 percent of people lost at least 10 ...

Eli Lilly will seek regulatory approval for its next-generation weight-loss pill by year-end, based on data that suggests it may not be as potent as injectable GLP-1 drugs on the market.

Eli Lilly is one step closer to bringing an oral weight loss medicine to the booming obesity drug market. A clinical trial ...

In a Phase 3 trial, drugmaker Eli Lilly and Company said it's oral GLP-1 pill showed similar results to injectable weight ...

A Seattle Kraken ice hockey player and the team's mascot had a close call with a grizzly bear during a promotional video shoot in Alaska. The run-in happened during a ...

Philadelphia Phillies reliever José Alvarado has rejoined the team following an 80-game suspension for violating baseball’s performance-enhancing drugs policy. Alvarado was back in ...

Weight-inclusive health care is the provision of equitable care without perpetuating weight stigma among patients of all body shapes and sizes.

The introduction of GLP-1s for weight loss has been a dysfunctional mess, thanks to pharmaceutical companies, insurance plans ...

The report, compiled for The New York Times by health analytics company Komodo Health, shows that denial rates rose from 18.3 ...

We're covering the myriad ways GLP-1 weight loss drugs are changing people's lives. (Photo illustration: Yahoo News; photos: ...